Oncology Mice Models Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

Description

Persistence Market Research has released an exhaustive analysis of the global Oncology Mice Models Market, providing a detailed examination of market dynamics, growth catalysts, challenges, and emerging trends. This report serves as an invaluable resource for stakeholders, offering comprehensive data and statistics to navigate the market landscape from 2024 to 2032.

The global oncology mice models market is poised for substantial growth, with a projected CAGR of 6% during the forecast period from 2024 to 2032. The market is anticipated to expand from an estimated value of US$ 390.3 Mn in 2024 to US$ 696.4 Mn by the end of 2032.

Key Insights:

Estimated Market Value (2024): US$ 390.3 Mn
Projected Market Value (2032): US$ 696.4 Mn
Global Market Growth Rate (CAGR 2024 to 2032): 6%

Oncology Mice Models Market - Report Scope:

The demand for oncology mice models is driven by the increasing prevalence of cancer worldwide and the need for effective preclinical testing of cancer therapies. Mice models play a crucial role in oncology research, providing valuable insights into tumor biology, drug efficacy, and treatment response. With advancements in genetic engineering and precision medicine, oncology mice models have become indispensable tools for drug discovery and development. Moreover, the growing adoption of personalized medicine approaches necessitates the use of mice models that recapitulate human cancer phenotypes, further driving market growth.

Market Growth Drivers:

The oncology mice models market is propelled by several factors including the rising incidence of cancer, increasing investment in cancer research, and technological advancements in mice modeling techniques. With cancer emerging as a leading cause of mortality worldwide, there is a growing urgency to develop novel therapeutics and improve treatment outcomes. Oncology mice models enable researchers to simulate human cancer conditions in laboratory settings, facilitating the development of targeted therapies and immunotherapies. Furthermore, collaborations between academic institutions, pharmaceutical companies, and contract research organizations (CROs) are fostering innovation and driving the adoption of advanced mice models in oncology research.

Market Restraints:

Despite the growing demand for oncology mice models, the market faces challenges related to ethical concerns, variability in experimental outcomes, and regulatory constraints. Ethical considerations surrounding the use of animals in research continue to be a subject of debate, prompting researchers to explore alternative methods such as in vitro models and computational simulations. Moreover, the inherent heterogeneity of tumors and genetic backgrounds in mice models can lead to variability in experimental results, complicating data interpretation and reproducibility. Additionally, stringent regulatory requirements for animal welfare and research standards pose compliance challenges for researchers and institutions involved in mice modeling studies.

Market Opportunities:

The oncology mice models market presents significant opportunities for innovation and collaboration across academia, industry, and government sectors. Advances in genome editing technologies such as CRISPR-Cas9 have revolutionized the generation of genetically engineered mice models with precise genetic alterations. These models enable researchers to study cancer pathways, tumor heterogeneity, and therapeutic responses with unprecedented accuracy. Furthermore, the integration of patient-derived xenograft (PDX) models and organoid cultures into preclinical oncology research provides valuable platforms for translational studies and personalized medicine initiatives. Leveraging these technologies and collaborative networks, stakeholders can accelerate the development of novel cancer therapies and improve patient outcomes.

Key Questions Addressed in the Report:

What is the Expected Value CAGR of the Oncology Mice Models Market?
What are the Key Factors Driving the Growth of the Oncology Mice Models Market?
Which Region Holds the Largest Market Share in the Oncology Mice Models Market?
Who are the Key Players in the Global Oncology Mice Models Market?
What Strategies are Adopted by Leading Companies to Sustain Growth in the Oncology Mice Models Market?

Competitive Landscape and Business Strategies:

Leading players in the oncology mice models market include Charles River Laboratories International, Inc., The Jackson Laboratory, and Taconic Biosciences, Inc. These companies focus on expanding their product portfolios, enhancing service offerings, and strengthening collaborative partnerships to maintain their competitive edge. Strategies such as investing in R&D, acquiring innovative technologies, and expanding global footprint are commonly employed to drive growth and market leadership. Additionally, initiatives to standardize experimental protocols, improve data reproducibility, and enhance animal welfare practices are integral to sustaining long-term growth and credibility in the oncology mice models market.

Key Companies Profiled:

Charles River Laboratories International, Inc.
The Jackson Laboratory
Taconic Biosciences, Inc.
Envigo Corporation
Crown Bioscience, Inc.
genOway S.A.
Horizon Discovery Group plc
Janvier Labs
Harbour BioMed
Champions Oncology, Inc.

Oncology Mice Models Market Segmentation:

By Product:

Humanized Immune System Mice Models
Syngeneic Tumor Mice Models
Immunodeficient Mice Models
NOG Mice Models
Spontaneous Tumor Mice Models
Others

By End User:

Contract Research Organizations
Pharma and Biopharma Companies
Academic and Research Institutes

By Region:

North America
Europe
Asia Pacific
Latin America
Middle East & Africa

Product Code: PMRREP33046

1. Executive Summary

1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations

2. Market Overview

2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions

3. Key Market Trends

3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends

4. Key Success Factors

4.1. Oncology Drugs - Pipeline Analysis
- 4.1.1. By Intervention
- 4.1.2. By Phase
- 4.1.3. By Funding Authority
4.2. Immuno-Oncology Drugs - Pipeline Analysis
- 4.2.1. By Phase
- 4.2.2. By Funding Authority
4.3. List of Pharma Companies That Have Ongoing Immuno-Oncology Clinical Trials
4.4. List of Academic & Research Institutes Involved In Ongoing Immuno-Oncology Clinical Trials
4.5. List of Preclinical CROs
4.6. Parent Market Analysis
4.7. Relative Number of Combination Oncology Therapy Trials
4.8. Landscape of Immuno-Oncology Drug Development
4.9. List of Preclinical immuno-oncology models
- 4.9.1. Cell lines
- 4.9.2. Mice Models
- 4.9.3. Organoids/ spheroids
4.10. Key Regulatory Scenario
4.11. Porter's Analysis
4.12. PESTLE Analysis
4.13. Supply Chain Analysis

5. Market Background

5.1. Macro-Economic Factors
- 5.1.1. Global GDP Growth Outlook
- 5.1.2. Global Healthcare Expenditure
5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Covid-19 Pandemic
- 5.2.2. Prevalence of cancer
- 5.2.3. Rise in R&D investments
- 5.2.4. Stringent Regulations
- 5.2.5. Rise in number of pre-clinical and clinical studies
- 5.2.6. Increasing investment in Cancer research
- 5.2.7. GDP Growth
- 5.2.8. Advancements in Models
5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis

6. COVID19 Crisis Analysis

6.1. Current COVID19 Statistics and Probable Future Impact
6.2. Current GDP Projection and Probable Impact
6.3. Current Economic Projection as compared to 2008 Economic analysis
6.4. COVID19 and Impact Analysis
6.5. Recovery Scenario - Short term, Midterm, and Long Term Impact

7. Global Oncology Mice Models Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
- 7.2.1. Y-o-Y Growth Trend Analysis
- 7.2.2. Absolute $ Opportunity Analysis

8. Global Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032, by Product

8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Product, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Product, 2024-2032
- 8.3.1. Humanized Immune System Mice Models
- 8.3.2. Syngeneic Tumor Mice Models
- 8.3.3. Immunodeficient Mice Models
- 8.3.4. NOG Mice Models
- 8.3.5. Spontaneous Tumor Mice Models
- 8.3.6. Others
8.4. Market Attractiveness Analysis By Product

9. Global Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032, by End User

9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By End User, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By End User, 2024-2032
- 9.3.1. Contract Research Organizations
- 9.3.2. Pharma and Biopharma Companies
- 9.3.3. Academic and Research Institutes
9.4. Market Attractiveness Analysis By Indication

10. Global Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032, by Region

10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
10.3. Current Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
- 10.3.1. The North America
- 10.3.2. Latin America
- 10.3.3. Europe
- 10.3.4. Asia Pacific
- 10.3.5. Middle East and Africa (MEA)
10.4 Market Attractiveness Analysis

11. North America Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032

11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
11.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 11.3.1. By Country
- 11.3.2. By Product
- 11.3.3. By End User
11.4. Market Attractiveness Analysis
11.5. Key Market Participants - Intensity Mapping
11.6. Drivers and Restraints - Impact Analysis

12. Latin America Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032

12.1. Introduction / Key Findings
12.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
12.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 12.3.1. By Country
- 12.3.2. By Product
- 12.3.3. By End User
12.4. Market Attractiveness Analysis
12.5. Key Market Participants - Intensity Mapping
12.6. Drivers and Restraints - Impact Analysis

13. Europe Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032

13.1. Introduction / Key Findings
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
13.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 13.3.1. By Country
- 13.3.2. By Product
- 13.3.3. By End User
13.4. Market Attractiveness Analysis
13.5. Key Market Participants - Intensity Mapping
13.6. Drivers and Restraints - Impact Analysis

14. Asia Pacific Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032

14.1. Introduction / Key Findings
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
14.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 14.3.1. By Country
- 14.3.2. By Product
- 14.3.3. By End User
14.4. Market Attractiveness Analysis
14.5. Key Market Participants - Intensity Mapping
14.6. Drivers and Restraints - Impact Analysis

15. Middle East and Africa (MEA) Oncology Mice Models Market Analysis 2019-2023 and Forecast 2024-2032

15.1. Introduction / Key Findings
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Market Size (US$ Mn) Forecast By Market Taxonomy, 2024-2032
- 15.3.1. By Country
- 15.3.2. By Product
- 15.3.3. By End User
15.4. Market Attractiveness Analysis
15.5. Key Market Participants - Intensity Mapping
15.6. Drivers and Restraints - Impact Analysis

16. Country Level Medical Cart Market Analysis and Forecast 2024 & 2032

16.1. Introduction
- 16.1.1. Market Value Proportion Analysis
- 16.1.2. Global VS. Country Growth Comparison
16.2. U.S. Medical Cart Market Analysis
- 16.2.1. By Product
- 16.2.2. By End User
16.3. Canada Medical Cart Market Analysis
- 16.3.1. By Product
- 16.3.2. By End User
16.4. Brazil Medical Cart Market Analysis
- 16.4.1. By Product
- 16.4.2. By End User
16.5. Argentina Medical Cart Market Analysis
- 16.5.1. By Product
- 16.5.2. By End User
16.6. Mexico Medical Cart Market Analysis
- 16.6.1. By Product
- 16.6.2. By End User
16.7. Germany Medical Cart Market Analysis
- 16.7.1. By Product
- 16.7.2. By End User
16.8. Italy Medical Cart Market Analysis
- 16.8.1. By Product
- 16.8.2. By End User
16.9. France Medical Cart Market Analysis
- 16.9.1. By Product
- 16.9.2. By End User
16.10. U.K. Medical Cart Market Analysis
- 16.10.1. By Product
- 16.10.2. By End User
16.11. Spain Medical Cart Market Analysis
- 16.11.1. By Product
- 16.11.2. By End User
16.12. BENELUX Medical Cart Market Analysis
- 16.12.1. By Product
- 16.12.2. By End User
16.13. Russia Medical Cart Market Analysis
- 16.13.1. By Product
- 16.13.2. By End User
16.14. China Medical Cart Market Analysis
- 16.14.1. By Product
- 16.14.2. By End User
16.15. Japan Medical Cart Market Analysis
- 16.15.1. By Product
- 16.15.2. By End User
16.16. India Medical Cart Market Analysis
- 16.16.1. By Product
- 16.16.2. By End User
16.17. Australia and New Zealand Medical Cart Market Analysis
- 16.17.1. By Product
- 16.17.2. By End User
16.18. GCC Countries Medical Cart Market Analysis
- 16.18.1. By Product
- 16.18.2. By End User
16.19. South Africa Medical Cart Market Analysis
- 16.19.1. By Product
- 16.19.2. By End User

17. Market Structure Analysis

17.1. Market Analysis by Tier of Companies
17.2. Market Share Analysis of Top Players

18. Competition Analysis

18.1. Competition Benchmarking
18.2. Competition Dashboard
18.3. Competition Deep Dive
- 18.3.1. The Jackson Laboratory
  - 18.3.1.1. Overview
  - 18.3.1.2. Product Portfolio
  - 18.3.1.3. Key Financials
  - 18.3.1.4. SWOT Analysis
  - 18.3.1.5. Sales Footprint
  - 18.3.1.6. Strategy Overview
    - 18.3.1.6.1. Marketing Strategy
    - 18.3.1.6.2. Product Strategy
    - 18.3.1.6.3. Channel Strategy
- 18.3.2. Taconic Biosciences
  - 18.3.2.1. Overview
  - 18.3.2.2. Product Portfolio
  - 18.3.2.3. Key Financials
  - 18.3.2.4. SWOT Analysis
  - 18.3.2.5. Sales Footprint
  - 18.3.2.6. Strategy Overview
    - 18.3.2.6.1. Marketing Strategy
    - 18.3.2.6.2. Product Strategy
    - 18.3.2.6.3. Channel Strategy
- 18.3.3. Charles River Laboratories
  - 18.3.3.1. Overview
  - 18.3.3.2. Product Portfolio
  - 18.3.3.3. Key Financials
  - 18.3.3.4. SWOT Analysis
  - 18.3.3.5. Sales Footprint
  - 18.3.3.6. Strategy Overview
    - 18.3.3.6.1. Marketing Strategy
    - 18.3.3.6.2. Product Strategy
    - 18.3.3.6.3. Channel Strategy
- 18.3.4. Shanghai Model Organisms Center Inc.
  - 18.3.4.1. Overview
  - 18.3.4.2. Product Portfolio
  - 18.3.4.3. Key Financials
  - 18.3.4.4. SWOT Analysis
  - 18.3.4.5. Sales Footprint
  - 18.3.4.6. Strategy Overview
    - 18.3.4.6.1. Marketing Strategy
    - 18.3.4.6.2. Product Strategy
    - 18.3.4.6.3. Channel Strategy
- 18.3.5. Envigo
  - 18.3.5.1. Overview
  - 18.3.5.2. Product Portfolio
  - 18.3.5.3. Key Financials
  - 18.3.5.4. SWOT Analysis
  - 18.3.5.5. Sales Footprint
  - 18.3.5.6. Strategy Overview
    - 18.3.5.6.1. Marketing Strategy
    - 18.3.5.6.2. Product Strategy
    - 18.3.5.6.3. Channel Strategy
- 18.3.6. Biocytogen
  - 18.3.6.1. Overview
  - 18.3.6.2. Product Portfolio
  - 18.3.6.3. Key Financials
  - 18.3.6.4. SWOT Analysis
  - 18.3.6.5. Sales Footprint
  - 18.3.6.6. Strategy Overview
    - 18.3.6.6.1. Marketing Strategy
    - 18.3.6.6.2. Product Strategy
    - 18.3.6.6.3. Channel Strategy
- 18.3.7. Genoway
  - 18.3.7.1. Overview
  - 18.3.7.2. Product Portfolio
  - 18.3.7.3. Key Financials
  - 18.3.7.4. SWOT Analysis
  - 18.3.7.5. Sales Footprint
  - 18.3.7.6. Strategy Overview
    - 18.3.7.6.1. Marketing Strategy
    - 18.3.7.6.2. Product Strategy
    - 18.3.7.6.3. Channel Strategy
- 18.3.8. Crown Bioscience Inc. (JSR Corporation).
  - 18.3.8.1. Overview
  - 18.3.8.2. Product Portfolio
  - 18.3.8.3. Key Financials
  - 18.3.8.4. SWOT Analysis
  - 18.3.8.5. Sales Footprint
  - 18.3.8.6. Strategy Overview
    - 18.3.8.6.1. Marketing Strategy
    - 18.3.8.6.2. Product Strategy
    - 18.3.8.6.3. Channel Strategy
- 18.3.9. Cyagen
  - 18.3.9.1. Overview
  - 18.3.9.2. Product Portfolio
  - 18.3.9.3. Key Financials
  - 18.3.9.4. SWOT Analysis
  - 18.3.9.5. Sales Footprint
  - 18.3.9.6. Strategy Overview
    - 18.3.9.6.1. Marketing Strategy
    - 18.3.9.6.2. Product Strategy
    - 18.3.9.6.3. Channel Strategy
- 18.3.10. Applied stem cells
  - 18.3.10.1. Overview
  - 18.3.10.2. Product Portfolio
  - 18.3.10.3. Key Financials
  - 18.3.10.4. SWOT Analysis
  - 18.3.10.5. Sales Footprint
  - 18.3.10.6. Strategy Overview
    - 18.3.10.6.1. Marketing Strategy
    - 18.3.10.6.2. Product Strategy
    - 18.3.10.6.3. Channel Strategy
- 18.3.11. Ingenious Targeting Laboratory
  - 18.3.11.1. Overview
  - 18.3.11.2. Product Portfolio
  - 18.3.11.3. Key Financials
  - 18.3.11.4. SWOT Analysis
  - 18.3.11.5. Sales Footprint
  - 18.3.11.6. Strategy Overview
    - 18.3.11.6.1. Marketing Strategy
    - 18.3.11.6.2. Product Strategy
    - 18.3.11.6.3. Channel Strategy
- 18.3.12. PolyGene - Transgenic mice model company
  - 18.3.12.1. Overview
  - 18.3.12.2. Product Portfolio
  - 18.3.12.3. Key Financials
  - 18.3.12.4. SWOT Analysis
  - 18.3.12.5. Sales Footprint
  - 18.3.12.6. Strategy Overview
    - 18.3.12.6.1. Marketing Strategy
    - 18.3.12.6.2. Product Strategy
    - 18.3.12.6.3. Channel Strategy
- 18.3.13. Creative Biolabs
  - 18.3.13.1. Overview
  - 18.3.13.2. Product Portfolio
  - 18.3.13.3. Key Financials
  - 18.3.13.4. SWOT Analysis
  - 18.3.13.5. Sales Footprint
  - 18.3.13.6. Strategy Overview
    - 18.3.13.6.1. Marketing Strategy
    - 18.3.13.6.2. Product Strategy
    - 18.3.13.6.3. Channel Strategy
- 18.3.14. TransCure Bioservices
  - 18.3.14.1. Overview
  - 18.3.14.2. Product Portfolio
  - 18.3.14.3. Key Financials
  - 18.3.14.4. SWOT Analysis
  - 18.3.14.5. Sales Footprint
  - 18.3.14.6. Strategy Overview
    - 18.3.14.6.1. Marketing Strategy
    - 18.3.14.6.2. Product Strategy
    - 18.3.14.6.3. Channel Strategy
- 18.3.15. Champions Oncology Inc
  - 18.3.15.1. Overview
  - 18.3.15.2. Product Portfolio
  - 18.3.15.3. Key Financials
  - 18.3.15.4. SWOT Analysis
  - 18.3.15.5. Sales Footprint
  - 18.3.15.6. Strategy Overview
    - 18.3.15.6.1. Marketing Strategy
    - 18.3.15.6.2. Product Strategy
    - 18.3.15.6.3. Channel Strategy
- 18.3.16. Certis Oncology
  - 18.3.16.1. Overview
  - 18.3.16.2. Product Portfolio
  - 18.3.16.3. Key Financials
  - 18.3.16.4. SWOT Analysis
  - 18.3.16.5. Sales Footprint
  - 18.3.16.6. Strategy Overview
    - 18.3.16.6.1. Marketing Strategy
    - 18.3.16.6.2. Product Strategy
    - 18.3.16.6.3. Channel Strategy
- 18.3.17. Signature
  - 18.3.17.1. Overview
  - 18.3.17.2. Product Portfolio
  - 18.3.17.3. Key Financials
  - 18.3.17.4. SWOT Analysis
  - 18.3.17.5. Sales Footprint
  - 18.3.17.6. Strategy Overview
    - 18.3.17.6.1. Marketing Strategy
    - 18.3.17.6.2. Product Strategy
    - 18.3.17.6.3. Channel Strategy
- 18.3.18. Pharmaron
  - 18.3.18.1. Overview
  - 18.3.18.2. Product Portfolio
  - 18.3.18.3. Key Financials
  - 18.3.18.4. SWOT Analysis
  - 18.3.18.5. Sales Footprint
  - 18.3.18.6. Strategy Overview
    - 18.3.18.6.1. Marketing Strategy
    - 18.3.18.6.2. Product Strategy
    - 18.3.18.6.3. Channel Strategy
- 18.3.19. Laboratory Corporation of America Holdings
  - 18.3.19.1. Overview
  - 18.3.19.2. Product Portfolio
  - 18.3.19.3. Key Financials
  - 18.3.19.4. SWOT Analysis
  - 18.3.19.5. Sales Footprint
  - 18.3.19.6. Strategy Overview
    - 18.3.19.6.1. Marketing Strategy
    - 18.3.19.6.2. Product Strategy
    - 18.3.19.6.3. Channel Strategy
- 18.3.20. Gempharmatech
  - 18.3.20.1. Overview
  - 18.3.20.2. Product Portfolio
  - 18.3.20.3. Key Financials
  - 18.3.20.4. SWOT Analysis
  - 18.3.20.5. Sales Footprint
  - 18.3.20.6. Strategy Overview
    - 18.3.20.6.1. Marketing Strategy
    - 18.3.20.6.2. Product Strategy
    - 18.3.20.6.3. Channel Strategy
- 18.3.21. Janvier Labs
  - 18.3.21.1. Overview
  - 18.3.21.2. Product Portfolio
  - 18.3.21.3. Key Financials
  - 18.3.21.4. SWOT Analysis
  - 18.3.21.5. Sales Footprint
  - 18.3.21.6. Strategy Overview
    - 18.3.21.6.1. Marketing Strategy
    - 18.3.21.6.2. Product Strategy
    - 18.3.21.6.3. Channel Strategy
- 18.3.22. Harbour BioMed
  - 18.3.22.1. Overview
  - 18.3.22.2. Product Portfolio
  - 18.3.22.3. Key Financials
  - 18.3.22.4. SWOT Analysis
  - 18.3.22.5. Sales Footprint
  - 18.3.22.6. Strategy Overview
    - 18.3.22.6.1. Marketing Strategy
    - 18.3.22.6.2. Product Strategy
    - 18.3.22.6.3. Channel Strategy